Discordance between HbA1c and fructosamine: evidence for a glycosylation gap and its relation to diabetic nephropathy
- PMID: 12502674
- DOI: 10.2337/diacare.26.1.163
Discordance between HbA1c and fructosamine: evidence for a glycosylation gap and its relation to diabetic nephropathy
Abstract
Objective: Discordances between HbA1c and other measures of glycemic control are common in clinical practice and remain unexplained. We developed a measure of discordance between HbA1c and fructosamine (FA) (glycosylated serum proteins) to conduct a systematic evaluation. We termed this the glycosylation gap (GG) and sought to determine its relationship to diabetic nephropathy.
Research design and methods: Measurements of HbA1c and FA on the same sample in 153 people were used to calculate GG, defined as the difference between measured HbA1c and HbA1c predicted from FA based on the population regression of HbA1c on FA.
Results: GG had a broad distribution (range, -3.2% to 5.5%); 40% of samples had values indicating major differences in prediction of complications risk by the measured versus predicted HbA1c. GG was highly correlated (r = 0.81) between measurements repeated in 65 patients 23 +/- 2 weeks apart, indicating that the discordances are reliable and not explained by differences in turnover of underlying proteins. In 40 patients with type 1 diabetes of >or = 15 years' duration, an increase in GG by 1% was associated with a 2.9-fold greater frequency of increasing nephropathy stage (P = 0.0014). GG was -0.8 +/- 0.2% in subjects with no nephropathy, -0.3 +/- 0.2% with microalbuminuria/hypertension, and 0.7 +/- 0.3% in subjects with proteinuria or renal dysfunction (P < 0.05). GG correlated better with nephropathy than did either HbA1c or FA alone in this population.
Conclusions: The glycosylation gap may be a useful clinical research tool for evaluating physiologic sources of variation in diabetic complications beyond glycemic control.
Similar articles
-
Progression of nephropathy in type 2 diabetes: the glycation gap is a significant predictor after adjustment for glycohemoglobin (Hb A1c).Clin Chem. 2011 Feb;57(2):264-71. doi: 10.1373/clinchem.2010.144949. Epub 2010 Dec 8. Clin Chem. 2011. PMID: 21147957
-
Variables involved in the discordance between HbA1c and fructosamine: the glycation gap revisited.PLoS One. 2013 Jun 12;8(6):e66696. doi: 10.1371/journal.pone.0066696. Print 2013. PLoS One. 2013. PMID: 23776693 Free PMC article.
-
Non-enzymatic glycosylation of immunoglobulins in diabetic nephropathy.Clin Chim Acta. 2004 Sep;347(1-2):169-76. doi: 10.1016/j.cccn.2004.04.016. Clin Chim Acta. 2004. PMID: 15313155
-
Frequency of HbA1c discordance in estimating blood glucose control.Curr Opin Clin Nutr Metab Care. 2008 Jul;11(4):512-7. doi: 10.1097/MCO.0b013e32830467bd. Curr Opin Clin Nutr Metab Care. 2008. PMID: 18542015 Review.
-
Effects comparison between low glycemic index diets and high glycemic index diets on HbA1c and fructosamine for patients with diabetes: A systematic review and meta-analysis.Prim Care Diabetes. 2015 Oct;9(5):362-9. doi: 10.1016/j.pcd.2014.10.008. Epub 2014 Dec 16. Prim Care Diabetes. 2015. PMID: 25524422 Review.
Cited by
-
High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: the Rotterdam Study.Diabetes Care. 2013 Jun;36(6):1619-28. doi: 10.2337/dc12-1188. Epub 2013 Jan 11. Diabetes Care. 2013. PMID: 23315602 Free PMC article.
-
Canine diabetes mellitus demonstrates multiple markers of chronic inflammation including Th40 cell increases and elevated systemic-immune inflammation index, consistent with autoimmune dysregulation.Front Immunol. 2024 Jan 22;14:1319947. doi: 10.3389/fimmu.2023.1319947. eCollection 2023. Front Immunol. 2024. PMID: 38318506 Free PMC article.
-
Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.Drug Des Devel Ther. 2013;7:99-104. doi: 10.2147/DDDT.S38346. Epub 2013 Feb 14. Drug Des Devel Ther. 2013. PMID: 23439744 Free PMC article. Clinical Trial.
-
Clinical usefulness of the measurement of serum fructosamine in childhood diabetes mellitus.Ann Pediatr Endocrinol Metab. 2015 Mar;20(1):21-6. doi: 10.6065/apem.2015.20.1.21. Epub 2015 Mar 31. Ann Pediatr Endocrinol Metab. 2015. PMID: 25883923 Free PMC article.
-
Protein glycation - biomarkers of metabolic dysfunction and early-stage decline in health in the era of precision medicine.Redox Biol. 2021 Jun;42:101920. doi: 10.1016/j.redox.2021.101920. Epub 2021 Feb 26. Redox Biol. 2021. PMID: 33707127 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous